Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Capital Expenditures (2017 - 2023)

Historic Capital Expenditures for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Q4 2023 value amounting to -$1000.0.

  • Rhythm Pharmaceuticals' Capital Expenditures changed 0.0% to -$1000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $47000.0, marking a year-over-year decrease of 8327.4%. This contributed to the annual value of $47000.0 for FY2023, which is 8327.4% down from last year.
  • According to the latest figures from Q4 2023, Rhythm Pharmaceuticals' Capital Expenditures is -$1000.0, which was down 0.0% from $1000.0 recorded in Q3 2023.
  • In the past 5 years, Rhythm Pharmaceuticals' Capital Expenditures registered a high of $2.3 million during Q2 2019, and its lowest value of -$1000.0 during Q4 2022.
  • Moreover, its 4-year median value for Capital Expenditures was $81500.0 (2021), whereas its average is $296214.3.
  • Within the past 5 years, the most significant YoY rise in Rhythm Pharmaceuticals' Capital Expenditures was 95833.33% (2022), while the steepest drop was 10147.06% (2022).
  • Over the past 4 years, Rhythm Pharmaceuticals' Capital Expenditures (Quarter) stood at $259000.0 in 2019, then plummeted by 73.75% to $68000.0 in 2021, then crashed by 101.47% to -$1000.0 in 2022, then changed by 0.0% to -$1000.0 in 2023.
  • Its last three reported values are -$1000.0 in Q4 2023, $1000.0 for Q3 2023, and $47000.0 during Q1 2023.